Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons

Annis Mechan, Jie Yuan, George Hatzidimitriou, Rodney J. Irvine, Una D McCann, George Ricaurte

Research output: Contribution to journalArticle

Abstract

A large body of data indicates that (±)3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') can damage brain serotonin neurons in animals. However, the relevance of these preclinical data to humans is uncertain, because doses and routes of administration used in animals have generally differed from those used by humans. Here, we examined the pharmacokinetic profile of MDMA in squirrel monkeys after different routes of administration, and explored the relationship between acute plasma MDMA concentrations after repeated oral dosing and subsequent brain serotonin deficits. Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h). MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5/100, similar to that in humans. MDMA accumulation in squirrel monkeys was nonlinear, and plasma levels were highly correlated with regional brain serotonin deficits observed 2 weeks later. The present results indicate that plasma concentrations of MDMA shown here to produce lasting serotonergic deficits in squirrel monkeys overlap those reported by other laboratories in some recreational 'ecstasy' consumers, and are two to three times higher than those found in humans administered a single 100-150 mg dose of MDMA in a controlled setting. Additional studies are needed on the relative sensitivity of brain serotonin neurons to MDMA toxicity in humans and non-human primates, the pharmacokinetic parameter(s) of MDMA most closely linked to the neurotoxic process, and metabolites other than MDA that may play a role.

Original languageEnglish (US)
Pages (from-to)339-350
Number of pages12
JournalNeuropsychopharmacology
Volume31
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Saimiri
Serotonin
Pharmacokinetics
Neurons
Brain
Primates

Keywords

  • Amphetamines
  • MDMA
  • Pharmacokinetics
  • Plasma
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys : Relationship to lasting effects on brain serotonin neurons. / Mechan, Annis; Yuan, Jie; Hatzidimitriou, George; Irvine, Rodney J.; McCann, Una D; Ricaurte, George.

In: Neuropsychopharmacology, Vol. 31, No. 2, 02.2006, p. 339-350.

Research output: Contribution to journalArticle

@article{2ad7738e31c84f2cb60b3d0e065fd1ba,
title = "Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons",
abstract = "A large body of data indicates that (±)3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') can damage brain serotonin neurons in animals. However, the relevance of these preclinical data to humans is uncertain, because doses and routes of administration used in animals have generally differed from those used by humans. Here, we examined the pharmacokinetic profile of MDMA in squirrel monkeys after different routes of administration, and explored the relationship between acute plasma MDMA concentrations after repeated oral dosing and subsequent brain serotonin deficits. Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h). MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5/100, similar to that in humans. MDMA accumulation in squirrel monkeys was nonlinear, and plasma levels were highly correlated with regional brain serotonin deficits observed 2 weeks later. The present results indicate that plasma concentrations of MDMA shown here to produce lasting serotonergic deficits in squirrel monkeys overlap those reported by other laboratories in some recreational 'ecstasy' consumers, and are two to three times higher than those found in humans administered a single 100-150 mg dose of MDMA in a controlled setting. Additional studies are needed on the relative sensitivity of brain serotonin neurons to MDMA toxicity in humans and non-human primates, the pharmacokinetic parameter(s) of MDMA most closely linked to the neurotoxic process, and metabolites other than MDA that may play a role.",
keywords = "Amphetamines, MDMA, Pharmacokinetics, Plasma, Serotonin",
author = "Annis Mechan and Jie Yuan and George Hatzidimitriou and Irvine, {Rodney J.} and McCann, {Una D} and George Ricaurte",
year = "2006",
month = "2",
doi = "10.1038/sj.npp.1300808",
language = "English (US)",
volume = "31",
pages = "339--350",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys

T2 - Relationship to lasting effects on brain serotonin neurons

AU - Mechan, Annis

AU - Yuan, Jie

AU - Hatzidimitriou, George

AU - Irvine, Rodney J.

AU - McCann, Una D

AU - Ricaurte, George

PY - 2006/2

Y1 - 2006/2

N2 - A large body of data indicates that (±)3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') can damage brain serotonin neurons in animals. However, the relevance of these preclinical data to humans is uncertain, because doses and routes of administration used in animals have generally differed from those used by humans. Here, we examined the pharmacokinetic profile of MDMA in squirrel monkeys after different routes of administration, and explored the relationship between acute plasma MDMA concentrations after repeated oral dosing and subsequent brain serotonin deficits. Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h). MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5/100, similar to that in humans. MDMA accumulation in squirrel monkeys was nonlinear, and plasma levels were highly correlated with regional brain serotonin deficits observed 2 weeks later. The present results indicate that plasma concentrations of MDMA shown here to produce lasting serotonergic deficits in squirrel monkeys overlap those reported by other laboratories in some recreational 'ecstasy' consumers, and are two to three times higher than those found in humans administered a single 100-150 mg dose of MDMA in a controlled setting. Additional studies are needed on the relative sensitivity of brain serotonin neurons to MDMA toxicity in humans and non-human primates, the pharmacokinetic parameter(s) of MDMA most closely linked to the neurotoxic process, and metabolites other than MDA that may play a role.

AB - A large body of data indicates that (±)3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') can damage brain serotonin neurons in animals. However, the relevance of these preclinical data to humans is uncertain, because doses and routes of administration used in animals have generally differed from those used by humans. Here, we examined the pharmacokinetic profile of MDMA in squirrel monkeys after different routes of administration, and explored the relationship between acute plasma MDMA concentrations after repeated oral dosing and subsequent brain serotonin deficits. Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h). MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5/100, similar to that in humans. MDMA accumulation in squirrel monkeys was nonlinear, and plasma levels were highly correlated with regional brain serotonin deficits observed 2 weeks later. The present results indicate that plasma concentrations of MDMA shown here to produce lasting serotonergic deficits in squirrel monkeys overlap those reported by other laboratories in some recreational 'ecstasy' consumers, and are two to three times higher than those found in humans administered a single 100-150 mg dose of MDMA in a controlled setting. Additional studies are needed on the relative sensitivity of brain serotonin neurons to MDMA toxicity in humans and non-human primates, the pharmacokinetic parameter(s) of MDMA most closely linked to the neurotoxic process, and metabolites other than MDA that may play a role.

KW - Amphetamines

KW - MDMA

KW - Pharmacokinetics

KW - Plasma

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=30944431901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944431901&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300808

DO - 10.1038/sj.npp.1300808

M3 - Article

C2 - 15999148

AN - SCOPUS:30944431901

VL - 31

SP - 339

EP - 350

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -